Cumberland Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Cumberland Pharmaceuticals Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue37.8739.5542.0135.9937.4434.3929.34
Cost of Revenue6.596.079.128.818.657.426.02
Gross Profit31.2833.4932.8927.1728.7926.9723.33
Operating Expenses
Research & Development4.825.836.695.685.776.877.58
Selling, General & Administrative28.1529.1026.2324.8024.9625.2524.16
Operating Expenses37.7143.0438.6034.8535.1736.2634.50
Operating Income-6.43-9.55-5.70-7.68-6.38-9.29-11.17
Other Income/Expense
Interest Income0.330.290.100.030.080.000.56
Interest Expense0.610.67-0.590.10-0.260.000.20
Other Income/Expense0.243.650.612.190.441.140.00
Income
Income Before Tax-6.47-6.28-5.58-5.56-6.57-9.29-10.80
Income Tax Expense-0.020.050.070.030.069.130.02
Net Income-6.48-6.28-5.57-3.51-3.34-3.54-6.96
Net Income - Continuous Operations-6.44-6.33-5.65-5.600.000.000.00
Net Income - Discontinued Operations0.000.000.001.990.000.000.00
EBITDA0.182.490.33-0.86-1.56-4.59-7.63
EBIT-5.86-5.62-5.00-5.46-6.31-9.04-10.61
Depreciation & Amortization4.758.105.074.374.434.132.77
Earnings Per Share
Basic EPS---1.00----
Diluted EPS---1.00----
Basic Shares Outstanding14.0614.3014.5614.9015.1615.4015.61
Diluted Shares Outstanding14.0614.3014.5614.9015.1615.4015.61